634 related articles for article (PubMed ID: 2421728)
21. Inhibition of cyclic AMP-dependent protein kinase activity by the cardiotonic drugs amrinone and milrinone.
Earl CQ; Linden J; Weglicki WB
Life Sci; 1986 Nov; 39(20):1901-8. PubMed ID: 2430162
[TBL] [Abstract][Full Text] [Related]
22. Biochemical studies on the mechanism of cardiotonic activity of MDL 17,043.
Kariya T; Wille LJ; Dage RC
J Cardiovasc Pharmacol; 1982; 4(3):509-14. PubMed ID: 6177950
[TBL] [Abstract][Full Text] [Related]
23. Biochemical mechanisms for the inotropic effect of the cardiotonic drug milrinone.
Earl CQ; Linden J; Weglicki WB
J Cardiovasc Pharmacol; 1986; 8(4):864-72. PubMed ID: 2427830
[TBL] [Abstract][Full Text] [Related]
24. Pig aortic endothelial-cell cyclic nucleotide phosphodiesterases. Use of phosphodiesterase inhibitors to evaluate their roles in regulating cyclic nucleotide levels in intact cells.
Souness JE; Diocee BK; Martin W; Moodie SA
Biochem J; 1990 Feb; 266(1):127-32. PubMed ID: 2155604
[TBL] [Abstract][Full Text] [Related]
25. Positive inotropic effect of amrinone in relation to cyclic nucleotide metabolism in the canine ventricular muscle.
Endoh M; Yamashita S; Taira N
J Pharmacol Exp Ther; 1982 Jun; 221(3):775-83. PubMed ID: 6283063
[TBL] [Abstract][Full Text] [Related]
26. Inotropic and chronotropic effects of 4-(4'-n-butylaniline)-7,8- dimethoxy-5H-pyrimido[5,4-b]indole in guinea-pig atria.
Castiella E; Frechilla D; Lasheras B; Cenarruzabeitia E; Martínez de Irujo JJ; Alberdi E; Santiago E; Monge A; Villanueva A; Martinez FJ
J Pharm Pharmacol; 1995 Jul; 47(7):601-7. PubMed ID: 8568629
[TBL] [Abstract][Full Text] [Related]
27. The inotropic effects of amrinone and milrinone on neonatal and young canine cardiac muscle.
Binah O; Sodowick B; Vulliemoz Y; Danilo P; Rosen M
Circulation; 1986 Mar; 73(3 Pt 2):III46-51. PubMed ID: 3002663
[TBL] [Abstract][Full Text] [Related]
28. The effect of cyclic AMP and cyclic GMP phosphodiesterase inhibitors on the superoxide burst of guinea-pig peritoneal macrophages.
Turner NC; Wood LJ; Burns FM; Gueremy T; Souness JE
Br J Pharmacol; 1993 Apr; 108(4):876-83. PubMed ID: 8387385
[TBL] [Abstract][Full Text] [Related]
29. High selectivity for inhibition of phosphodiesterase III and positive inotropic effects of MCI-154 in guinea pig myocardium.
Bethke T; Meyer W; Schmitz W; Scholz H; Wenzlaff H; Armah BI; Brückner R; Raap A
J Cardiovasc Pharmacol; 1993 Jun; 21(6):847-55. PubMed ID: 7687707
[TBL] [Abstract][Full Text] [Related]
30. Resolution of soluble cyclic nucleotide phosphodiesterase isoenzymes, from liver and hepatocytes, identifies a novel IBMX-insensitive form.
Lavan BE; Lakey T; Houslay MD
Biochem Pharmacol; 1989 Nov; 38(22):4123-36. PubMed ID: 2480793
[TBL] [Abstract][Full Text] [Related]
31. Species-dependent pharmacodynamic effects of the selective low Km cyclic AMP phosphodiesterase III inhibitors WIN 58993 and WIN 62005.
Dundore RL; Pagani ED; Bode DC; Bacon ER; Singh B; Lesher GY; Buchholz RA; Silver PJ
J Cardiovasc Pharmacol; 1995 Jan; 25(1):14-21. PubMed ID: 7723343
[TBL] [Abstract][Full Text] [Related]
32. The effect of phosphodiesterase III inhibitors on human neutrophil function.
Mikawa K; Akamatsu H; Nishina K; Shiga M; Maekawa N; Obara H; Niwa Y
Crit Care Med; 2000 Apr; 28(4):1001-5. PubMed ID: 10809273
[TBL] [Abstract][Full Text] [Related]
33. Effects of phosphodiesterase inhibitors, imidazole and phosphate on cyclic CMP phosphodiesterase are different from those on cyclic AMP and cyclic GMP phosphodiesterases.
Kuo JF; Shoji M; Brackett NL; Helfman DM
J Cyclic Nucleotide Res; 1978 Dec; 4(6):463-74. PubMed ID: 85641
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of human cardiac cyclic AMP-phosphodiesterases by R 80122, a new selective cyclic AMP-phosphodiesterase III inhibitor: a comparison with other cardiotonic compounds.
de Cheffoy de Courcelles D; de Loore K; Freyne E; Janssen PA
J Pharmacol Exp Ther; 1992 Oct; 263(1):6-14. PubMed ID: 1328613
[TBL] [Abstract][Full Text] [Related]
35. Role of cyclic AMP- and cyclic GMP-phosphodiesterases in the control of cyclic nucleotide levels and smooth muscle tone in rat isolated aorta. A study with selective inhibitors.
Schoeffter P; Lugnier C; Demesy-Waeldele F; Stoclet JC
Biochem Pharmacol; 1987 Nov; 36(22):3965-72. PubMed ID: 2825708
[TBL] [Abstract][Full Text] [Related]
36. Inotropic effects of amrinone and milrinone on contraction and relaxation of isolated cardiac muscle.
Sys SU; Goenen MJ; Chalant CH; Brutsaert DL
Circulation; 1986 Mar; 73(3 Pt 2):III25-35. PubMed ID: 3002662
[TBL] [Abstract][Full Text] [Related]
37. The two mechanisms of action of racemic cardiotonic EMD 53998, calcium sensitization and phosphodiesterase inhibition, reside in different enantiomers.
Lues I; Beier N; Jonas R; Klockow M; Haeusler G
J Cardiovasc Pharmacol; 1993 Jun; 21(6):883-92. PubMed ID: 7687712
[TBL] [Abstract][Full Text] [Related]
38. Cardiac effects of R 79595 and its isomers (R 80122 and R 80123) in an acute heart failure model. A new class of cardiotonic agents with highly selective phosphodiesterase III inhibitory properties.
Schneider J; Beck E; Heers C; Conrad C; de Chaffoy de Courcelles D; Wilffert B; Peters T
Naunyn Schmiedebergs Arch Pharmacol; 1992 Nov; 346(5):563-72. PubMed ID: 1470228
[TBL] [Abstract][Full Text] [Related]
39. Two inotropes with different mechanisms of action: contractile, PDE-inhibitory and direct myofibrillar effects of levosimendan and enoximone.
Szilágyi S; Pollesello P; Levijoki J; Haikala H; Bak I; Tósaki A; Borbély A; Edes I; Papp Z
J Cardiovasc Pharmacol; 2005 Sep; 46(3):369-76. PubMed ID: 16116344
[TBL] [Abstract][Full Text] [Related]
40. Cardiotonic actions of selective phosphodiesterase inhibitors in rat isolated ventricular cardiomyocytes.
Kelso EJ; McDermott BJ; Silke B
Br J Pharmacol; 1993 Dec; 110(4):1387-94. PubMed ID: 8306078
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
